Phenzyme Inc has been working on development of an enzyme that degrades the extracellular matrix surrounding solid tumors specifically while avoiding systemic activity. These therapeutics enzymes are designed specifically to target extracellular matrix in the tumor micro-environment. With the firm's enzyme drug acting on the extracellular matrix, it can serve to enhance the efficacy of broad range of cancer therapeutics in solid tumors and the extracellular matrix. This can limit the ability of cancer drugs to penetrate and act on cancer cells - effectively enabling clinicians to get an enzyme that increases tumor drug exposure, reduces adverse events and improves immune responses.
